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EDITORIALS
Reimagining Long-term Antibiotics in Persons Who Inject Drugs:
Time to Shift the Status Quo?
Jesse Theisen-Toupal, MD1,2,3*, Elana S. Rosenthal, MD4, Christopher F. Rowley, MD, MPH5,6,7
1Medical Service, Veterans Affairs Medical Center, Washington, DC; 2George Washington University School of Medicine and Health Sciences,
Washington, DC; 3Uniformed Services University of the Health Sciences, Bethesda, Maryland; 4DC Partnership for HIV/AIDS Progress, Washington,
DC; 5Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts; 6Harvard Medical School, Boston, Massachu-
setts; 7Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
In the United States, there are an estimated 744,000
individuals who have engaged in recent injection drug
use (IDU) and 6.6 million individuals who have ever
injected a drug.1 The practice of IDU predisposes indi-
viduals to serious bacterial and fungal infections that
often require long-term intravenous antibiotics. In
individuals without IDU, these serious infections are
often treated with outpatient parenteral antibiotic
therapy (OPAT). However, a different standard exists
for many persons who inject drugs (PWID)—the man-
dated completion of antibiotics in an inpatient setting.
Though mandating inpatient antibiotic therapy for
PWID is a widely adopted standard, this practice is
not evidence based and may increase overall costs to
the healthcare system. In 2012, in a quality-
improvement initiative, UKHealthCare established a
protocol for treating appropriate PWID with OPAT.2
They found very few inpatient providers willing to
discharge PWID on OPAT, even with an established
protocol.
To better understand the reasons for the low adop-
tion of this protocol, Fanucchi and colleagues devel-
oped a survey designed to “assess attitudes, practices,
and mediating factors impacting the decision making
about discharging PWID on OPAT.”2 The results of
this survey are reported in this issue of the Journal of
Hospital Medicine.
The study found that 95% of inpatient providers
use OPAT for patients without IDU, but only 29%
would even consider OPAT in PWID. The most com-
mon barriers to discharging a patient with IDU on
OPAT were socioeconomic factors, willingness of
infectious diseases physicians to follow as an outpa-
tient, and concerns for misuse of peripherally inserted
central catheters and adherence with antibiotic
treatment.
At first glance, these reservations seem very reason-
able. The presence of socioeconomic factors such as
homelessness or lack of infectious diseases specialist
follow-up would make the risks of discharge on
OPAT significant. The concerns for misuse of periph-
erally inserted central catheters and adherence to anti-
biotic treatment suggest that inpatient providers have
an overall goal of reducing drug misuse and improv-
ing treatment outcomes.
Unfortunately, there are no data to suggest that
completion of antibiotics in an inpatient setting
reduces drug misuse or improves adherence to antibi-
otic treatments. Studies have found that at least 16%
of PWID will misuse drugs during their hospitaliza-
tion,3 and 25% to 30% will be discharged against
medical advice.3,4 This may be in large part due to
the fact that inpatient providers are historically poor
at addressing substance use disorders, even in patients
with serious infections associated with IDU.5 Yet the
provision of methadone during hospitalization has
been associated with a significant reduction in dis-
charges against medical advice.4 Rather than focusing
on placing restrictions on individuals with risky
behaviors, patients may benefit more from minimizing
these risks through prompt recognition and manage-
ment of substance use disorder.
Although limited, there is also evidence to support
the feasibility of safe and effective OPAT in some
PWID. A study by Ho et al. used OPAT to treat 29
PWID hospitalized with serious infections.6 The study
population had adequate housing, a reliable guardian,
and signed a contract agreeing to abstain from drug
misuse. In addition, all patients received substance use
counseling and novel tamper-proof security seals to
prevent misuse of peripherally inserted central cathe-
ters, and antibiotics were delivered daily at an infu-
sion center. They found no evidence of line
tampering, excess readmissions, or excess line infec-
tions. Of note, the study population included 2
patients who were discharged against medical advice
but successfully completed OPAT without issue.
Although we do not believe that all individuals are
appropriate for OPAT, this study suggests that OPAT
can be considered in select PWID.
The study by Fanucchi et al. also reinforces the
importance of making individualized risk assessments
of persons with a history of IDU rather than assuming
uniformity among the population. Of particular note
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is the lack of agreed-upon definition of “remote” his-
tory of IDU (range, 2–120 months; median, 12
months). The idea that individuals with a decade of
sobriety could be subject to the same restrictions as a
patient injecting multiple times a day speaks to pro-
viders’ discomfort with assessing the individual risk of
a person who has suffered from substance use disor-
der. Further, the fact that so few providers felt sub-
stance use disorder treatment was a critical
component of a decision to allow OPAT raises con-
cerns that providers are not aware of effective means
to treat addiction. In particular, it is crucial for
providers to understand that medication-assisted
treatment, such as methadone or buprenorphine for
opioid use disorder, has significant evidence to sup-
port efficacy in decreasing drug misuse and improving
outcomes.
This study suggests more work will need to be done
before inpatient providers will be comfortable dis-
charging any PWID with OPAT. This includes
improved outpatient services (enhanced case manage-
ment and home health services, and better access to
outpatient physicians including infectious diseases spe-
cialists), the development of tamper-evident devices to
deter misuse of peripherally inserted central catheters,
and defined legal protection for providers.
In addition, more research needs to be done on this
population to objectively stratify risk for PWID and
assess outcomes for PWID treated with OPAT versus
the current standard of care. This research should
have a particular focus on the long-term financial and
societal costs associated with PWID leaving against
medical advice or receiving potentially unnecessary
inpatient services. Minimizing the length of stay may
defray inpatient costs and afford investment into more
robust, effective outpatient services. It is essential that
we develop a system to provide antibiotics in a way
that optimizes outcomes and is cost-effective.
Regardless of the decision to mandate antibiotic
treatment in an inpatient setting or to discharge with
OPAT, it is clear that more needs to be done to
address addiction in hospitalized patients. All hospi-
talized PWID should receive safe injection education
and a referral to a substance use disorder specialist. In
addition, individuals with opioid-misuse or opioid use
disorder should receive opioid overdose education and
naloxone distribution. Hospitalizations serve as
important opportunities to engage individuals in the
treatment of their addiction. It is essential that hospi-
talists begin utilizing these opportunities.
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